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LABA – long-acting beta-agonists 
NSAIDs – exacerbated respiratory disease 
OR – odds ratio 
pDCs – plasmacytoid dendritic cells 
SABA – short-acting beta-agonists
INTRODUCTION
CRS is one of the most widespread chronic diseases in the world, 
affecting 10.9% of the Europe’s population [1] and 12.5% of the 
US population [2]. Chronic sinusitis is a complex systemic dis-
ease. Clinically, based on endoscopic examination, two major CRS 
phenotypes can be distinguished, namely CRSwNP and CRSsNP. 
Clinically distinguished phenotypes do not reflect the profile of 
AbbRevIATIONs
AERD – aspirin-exacerbated respiratory disease 
AFRS – allergic fungal rhinosinusitis 
CF – cystic fibrosis 
CRS – chronic rhinosinusitis  
CRSsNP – CRS without nasal polyps 
CRSwNP – CRS with nasal polyps 
DCs – dendritic cells 
EAACI – European Academy of Allergy and Clinical Immunology 
ECP – eosinophil cationic protein  
EFRS – eosinophilic fungal rhinosinusitis 
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AbsTRACT:   Introduction: CRS is a complex systemic disease affecting more than 10% of the population. There are two main types of CRS 
phenotypes: CRSwNP and CRSsNP. In the Caucasian population, the prevalence of inflammation markers typical of the Th1 
profile is observed in CRSsNP, whereas Th2 and Th17 in CRSwNP. Th2 inflammation is observed in the CRSwNP phenotype 
with concomitant allergies, asthma or hypersensitivity to NSAIDs. 
  Objectives: The aim of the study was to evaluate, based on the authors’ own material, whether allergies, asthma or hypersensi-
tivity to NSAIDs were a risk factor for the development of a specific CRS phenotype. An attempt was also made to investigate the 
influence of comorbidities on the extent of sinus endoscopic procedures, which depended on the severity of inflammation.
  Methods: In the years 2006–2015, ESS was performed on 2217 patients with different CRS phenotypes. Patients with an allergy, 
bronchial asthma and hypersensitivity to NSAIDs were subjected to analysis.
  Results: Based on logistic regression, it was found that among the mentioned comorbidities, only asthma (P < 0.0001) and 
hypersensitivity to NSAIDs (P = 0.0007) significantly affect the occurrence of the phenotype with polyps, whereas the impact 
of allergies is statistically insignificant (P = 0.1909). The relationship between the type of ESS and CRS phenotypes is statisti-
cally significant (P < 0.0001).
  Conclusions: Bronchial asthma and hypersensitivity to NSAIDs have a statistically significant effect on the occurrence of the 
CRSwNP phenotype. This effect was not observed in allergies. The impact of allergies, asthma and hypersensitivity on the 
phenotype was observed in the group of patients subjected to the most extensive surgery (ESS 4).
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Extent of surgery
The extent of endoscopic sinus surgery is defined as type 1–4:
•	 the first type involves the removal of the uncinate process 
with the enlargement of the maxillary ostium (antrostomy 
with uncinectomy);
•	 the second type involves the opening of the anterior 
or anterior and posterior ethomoidal cells (anterior or 
anterior and posterior ethmoidectomy);
•	 the third type involves the opening of the frontal sinus 
(with or without antroethmoidectomy);
•	 the fourth one – the opening of the sphenoid sinus 
(operated in conjunction with other sinuses or not).  
The authors adopted the above description of ESS types in order 
to group the procedures performed depending on the number and 
type of sinuses. The surgery was performed under general anaes-
thesia with hypotension.
Inclusion criteria
Patients who had reported nasal obstruction or discharge and at 
least one of the other symptoms, such as impaired olfaction or fa-
cial pain lasting over 12 weeks with no complete resolution after 
maximal medical therapy, were qualified for surgery in accordance 
with the EPOS 2012 guidelines [11]. For 504 patients (22.73% of 
the total number of patients), these were reoperations of the nasal 
cavity and sinuses. For the remaining 1713 (77.27%), these were 
the first operations. CRS phenotypes were identified after nasal 
endoscopy. CRSwNP was diagnosed when bilateral polyps were 
visualised at least in the middle nasal meatus. Nasal polyposis in 
CRSwNP was categorized using the Lund-Kennedy scoring system.
A CT scan of the sinuses was performed in each patient, on the 
basis of which the extent of inflammatory lesions was assessed ac-
cording to the Lund-Mackay score (the degree of opacification in 
the maxillary, anterior and posterior ethmoid, frontal, and sphe-
noid sinuses as well as the obstruction of the ostiomeatal complex-
es were evaluated (on both sides) on a 0–2 scale – a maximum of 
24 points), and then the extent of ESS was planned. The patients 
admitted to the ward for endoscopic surgery were diagnosed and 
treated on an outpatient basis due to chronic sinusitis and asso-
ciated conditions such as allergies, bronchial asthma and hyper-
sensitivity to NSAIDs. Tab. I. shows the number of patients with 
respect to the comorbidities. The patients were allocated to three 
groups depending on the comorbidities. However, one patient 
could belong to one, two or all three of them.
The first group included patients with IgE-dependent allergies to 
seasonal (early and late blooming trees, grasses, weeds) and perennial 
airborne allergens (mites and mould spores, cat and dog allergens). 
The patients had allergic reactions to one or several different allergens. 
The studied plant and fungal allergens were characteristic of the 
temperate climate of Central Europe. This group included patients 
reporting clinical symptoms caused by the allergens. Allergies 
were confirmed by a skin prick test or the presence of specific IgE 
antibodies in the patient’s serum. The examinations were performed 
cytokines involved in the inflammation process. Tomassen et al. 
[3] defined CRS endotypes as „subtypes of disease with a unique 
pathomechanism, functionally and pathologically different from 
others by the involvement of a specific molecule or cell”. Over-
lapping cytokines of the inflammation profile with the predomi-
nance of Th1, Th2 and Th17 helper lymphocytes are involved in 
CRS. In the Caucasian population, the prevalence of inflamma-
tion markers typical of the Th1 profile is observed in CRSsNP, 
whereas Th2 and Th17 in CRSwNP. Th2 inflammation with a high 
predominance of IL-5, causing subsequent tissue eosinophilia, is 
observed in the CRSwNP phenotype with concomitant asthma. 
Eosinophilic sinusitis is also observed in patients with respira-
tory diseases caused by IgE-related allergy or aspirin hypersen-
sitivity (NERD) [4], EFRS [5] and AFRS [2]. CRSwNP with the 
predominance of neutrophilic inflammation (Th1 type) occurs 
in the case of blockage of the sinus ostia due to congenital ana-
tomical malformations, chronic (allergic or nonallergic) rhinitis 
and CF or primary ciliary dyskinesia [4].
The aim of the study was to investigate whether comorbidities 
accompanied by inflammation with a predominant role of 
eosinophils such as allergies, asthma or NSAIDs hypersensitivity 
were equally important risk factors for the development of 
a specific CRS phenotype. Among Caucasians, eosinophilic 
infiltrates are mainly found in polyps, which suggests a common 
pathomechanism of upper and lower airway inflammation. In 
the existing literature, there are reports suggesting the impact 
of asthma, IgE-dependent allergy and AERD on the severity of 
CRSwNP and the extent and frequency of sinus reoperation 
[6–10]. This was a stimulus for verifying, based on the authors’ 
own material, whether these comorbidities had an effect on the 
severity of inflammatory changes in the sinuses and, as a result, 
on the extent of endoscopic surgery.
The authors also decided to evaluate the relationships between CRS 
phenotypes and comorbidities such as allergies, asthma or hypersen-
sitivity to NSAIDs and check if these relationships were similar in 
the groups divided based on the extent of endoscopic sinus surgery.
The authors of the study carried out a retrospective analysis of 
all the patients (only 1% of patients who met the exclusion crite-
rion described below were excluded from the analysis) admitted, 
qualified and operated on due to CRS in the years 2006–2015. The 
demographic data, disease phenotype and concurrent conditions 
related to asthma, allergies and NSAIDs hypersensitivity as well as 
the extent of ESS were taken into account. The relationship between 
CRS phenotypes and the aforementioned diseases was assessed.
MATeRIAL AND MeTHODs
Study population
In the years 2006–2015, ESS was performed on 2217 patients over 
the age of 18 with CRSsNP or CRSwNP. The study group consist-
ed of 1021 women (46.05% of all patients) and 1196 men (53.95% 
of all). The average age of women was 48.03 ± 13.41, while that of 
men was 46.91 ± 14.55. They all belonged to the Caucasian race.
www.otolaryngologypl.com10
original article
trolled bronchial asthma, documented IgE-dependent allergies to 
grass, tree or weed pollen currently present in the environment, 
immunodeficiency, CF and those with tumours identified in the 
histopathological examination of the material collected from the 
sinuses were excluded from the study.
Statistical Analysis
Statistical analysis was performed using Statistica 12.5. The analysis 
was divided into two parts. First, the influence of each comorbid-
ity (allergies, asthma or hypersensitivity) on CRS phenotypes was 
analysed separately (one-dimensional analysis, each comorbidity – 
dichotomous variable – was treated in the analysis as a single quali-
tative predictor). Thus, 3 groups were separated according to the 
on an outpatient basis and correlated with clinical symptoms 
occurring in the patients. The patients were under constant care of 
an allergist who applied the maximal medical therapy, some patients 
were also subjected to specific allergen immunotherapy. Skin prick 
or in vitro tests were not performed in every patient admitted to the 
ward. It was assumed that a positive test without clinical symptoms 
did not qualify patients to the group with allergies. The patients with 
clinical symptoms and positive pollen allergy tests were operated 
outside of the pollen season for specific allergens. Patients with 
allergic reactions occurring in other immunological mechanisms 
were not qualified here (non-IgE-dependent allergies).
The second group included patients with NSAIDs hypersensitiv-
ity. AERD is „a complex syndrome typified by underlying airway 
inflammation in which patients experience adult-onset asthma, 
nasal polyposis/chronic rhinosinusitis, and aspirin/nonsteroidal 
anti-inflammatory drug (NSAID) sensitivity” [12]. The authors 
adopted the term „hypersensitivity to NSAIDs” which is defined by 
the EAACI as objectively reproducible symptoms that are caused 
by exposure to a specific stimulus in a dose tolerated by other 
people. Clinical symptoms relate to the mucous membranes of 
the respiratory and digestive tract as well as the skin, and can be 
induced not only by aspirin, but also by one or more NSAIDs [13].
Patients, qualified to this group by the authors, who reported hy-
persensitivity to aspirin and other NSAIDs had dyspnoea attacks, 
serous fluid discharge/nasal mucosa oedema or acute urticaria af-
ter taking the drugs. Aspirin tests were not performed in patients 
after their admission to the ward. It was the medical history de-
scribing the symptoms resulting from taking the drug/s that played 
the crucial role. Information about unexpected symptoms after 
taking NSAIDs was provided during a medical interview, not in 
the form of a questionnaire. Not all patients with hypersensitivity 
to NSAIDs had asthma, some patients reported inhalant allergies.
The third group included patients with bronchial asthma diagnosed 
in the outpatient setting. According to GINA [14], asthma is a het-
erogeneous disease defined by a medical interview, with respiratory 
symptoms such as wheezing, dyspnoea, chest tightness and cough-
ing, which vary over time and in terms of severity, including variable 
airway obstruction. Patients with co-existing asthma, depending 
on the severity of asthma (light, moderate, severe), took SABA, ICS 
combined or not with LABA and/or antileukotriene drugs. Chronic 
treatment in outpatient care was recommended by a specialist. The 
actual (the last 4 weeks before the surgical treatment) level of asthma 
control (good, partial or bad) was important for the authors. Asthma 
was considered well-controlled when the patient did not report any 
nocturnal symptoms, daily symptoms were less frequent than twice 
a week, drugs (SABA) were used less than twice a week, and if the 
disease had no effect on daily activities. In terms of the severity of 
asthma, assessed on the basis of recommended doses of inhalation 
drugs and the FEV1 index, patients with mild and moderately severe 
asthma were qualified for surgical treatment of the sinuses.
Exclusion criteria
Patients under 18 years of age with rhinosinusitis exacerbation 
less than 4 weeks prior to the admission to hospital, poorly con-
Tab. I.  Number of patients with respect to comorbidities.
COMORbIDITy DIAGNOsIs
TOTAL
ALLeRGy HypeRseNsITIvITy AsTHMA CRswNp CRssNp
– – – 539 957 1496 1496
+ + – 62 99 161
– – – 35 48 83
– – + 140 84 224
+ + – 8 3 11 721
+ + + 50 24 74
– – + 104 32 136
+ + + 25 7 32
Σ+ = 278 Σ+ = 278 Σ+ = 466 Σ = 963 Σ = 1254 Σ = 2217
„+”  indicates the occurrence of a given disease, „–” means the absence of a given disease, e.g. 
in the second row of the table where „+” is only in the allergy column, 161 people out of all 
2217 patients had allergies without co-existing hypersensitivity (–) or asthma (–); of the 161 
patients, 62 had CRSwNP, the other patients (99) – CRSsNP; 721 out of 2217 patients had at 
least one comorbidity, and 32 patients had all three.
Tab. II.  Relationship between comorbidities and diagnosis. 
DIAGNOsIs
COMORbIDITy
ALL pATIeNTs N = 2217
CRswNp
Nwp = 963 
(43,44% z N)
CRssNp
NNp = 1254
(56,54% z N)
p – vALUe
Allergy
Yes 
(278 per.) 
12,54% z n
52,16% 47,84%
p = 0.0017 *
Nie  
(1939 per.) 
87.46% z n
42,19% 57,81%
Hypersensitivity
Yes 
(262 per.) 
11,82% z n
65,65% 34,35%
p < 0.0001
Nie  
(1955 per.) 
88,18% z n
40,46% 59,54%
Asthma
Yes 
(466 per.) 
21,02% z n
68,45% 31,55%
p < 0.0001
Nie  
(1751 per.) 
78,98% z n
36,78% 63,22%
* P < 0.01, P-values obtained from the Chi2 test, which checks whether there is a relationship 
between the occurrence of a particular comorbidity and CRS phenotype.
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hypersensitivity to NSAIDs, 172 (65.65%) had polyps, and in 90 
(34.35%) they were absent. Of all 963 patients with CRSwNP, 172 
(17.86%) reported hypersensitivity. In the group without polyps, 
which included 1254 patients, only 90 (7.18%) reported hypersen-
sitivity. The occurrence of hypersensitivity is associated with the 
presence of polyps (P < 0.0001) (Tab. II.).
Asthma vs. CRS phenotype
Bronchial asthma was present in 466 patients (21.02% out of 2217). 
In the group of patients with bronchial asthma, 319 (68.45%) had 
polyps, whereas in 147 (31.55%) they were absent. Among 963 
patients with CRSwNP, 33.13% suffered from bronchial asthma. 
The relationship between the occurrence of bronchial asthma and 
the diagnosis is statistically significant (P < 0.0001) (Tab. II.). It is 
more common in the group with polyps.
ESS type vs. CRS phenotype vs. comorbidities
In this part, it was decided to check whether the above relation-
ships were similar in nature in the groups divided in terms of the 
extent of surgery. For this purpose, the entire study group was 
divided with respect to the ESS type, thus obtaining four groups 
analysed independently.
Of all 2217 cases, the ESS 1 group was the largest (863; 38.93% of 
all the treated patients), whereas the ESS 3 group the smallest (42; 
1.89% of 2217). In the other groups, namely ESS 2 and ESS 4, the 
numbers were comparable and amounted to 654 (29.50%) and 658 
(29.68%), respectively (Tab. III.).
The relationship between ESS and primary diagnosis is statistically 
significant (P < 0.0001). In the CRSsNP group, ESS 1 accounted for 
more than half of all the cases (54.94%); the other types 2, 3 and 4 ac-
counted for 24.56%, 1.59% and 18.9%, respectively. In the CRSwNP 
group, ESS 4 was most common (43.72%), and the other types, 1, 
2, and 3 accounted for 18.07%, 35.93% and 2.28%, respectively. The 
ESS 1 group was mainly dominated by cases without polyps (79.84% 
of all people with ESS 1), whereas those with polyps prevailed in the 
other ESS groups: 52.91% (ESS 2), 52.38% (ESS 3), and 63.98% (ESS 4).
description given in the „Inclusion criteria”, and in each of them the 
relationship between the phenotype and one particular comorbid-
ity was analysed individually. The same analysis was also performed 
after dividing each of the three groups into subgroups relative to the 
extent of surgery. For this purpose, the Chi2 test was used. In justi-
fied cases, the Chi2 test with the appropriate correction was used. In 
the second stage, it was examined which of the three comorbidities 
(three qualitative predictors in the analysis) affect the phenotypes. 
For this purpose, a multivariate analysis based on logistic regres-
sion (logit) was performed. OR was used as the measure of effect. 
ResULTs
In the study group of 2217, there were 1254 (56.56% of total patients) 
patients with CRSsNP and 963 (43.44%) with CRSwNP. The group 
with CRSsNP included 616 women and 638 men. The CRSwNP 
phenotype occurred in 405 women and 558 men. The relationship 
between diagnosis and gender is statistically significant (P = 0.0009). 
Women were more likely than men to suffer from CRSsNP – 60.33% 
(616 out of 1021 women). A total of 53.34% of men (638 out of 
1196 men) were diagnosed with CRSsNP, and polyps were present 
in 46.66%. However, the influence of gender on the occurrence of 
a particular phenotype was not taken into account in further analysis.
Allergy vs. CRS phenotype
Of all 2217 patients, 278 (12.54% of all the treated patients) had 
allergies (Tab. II.). Among patients with an allergy, 145 (52.16% 
of 278) had CRSwNP. The other 133 (47.84% of 278) – CRSsNP. 
As many as 1121 individuals (57.81% of 1939 patients without an 
allergy) were diagnosed with CRSsNP. The relationship between 
the occurrence of allergies and diagnosis is statistically significant 
(P = 0.0017) (Tab. II.). At this stage, the occurrence of the phenotype 
with polyps seems to be associated with the presence of allergies.
NSAID vs. CRS phenotype
Hypersensitivity to NSAIDs was present in 262 cases (11.82% of 
all the 2217 operated patients) (Tab. II.). Among patients with 
Tab. III.  Distribution of the number of patients in relation to the diagnosis, extent of surgery and comorbidities. 
COMORbIDITy exTeNT OF sURGeRy
ess 1 ess 2 ess 3 ess 4
ALLeRGy HypeRseNsITIvITy AsTHMA DIAGNOsIs DIAGNOsIs DIAGNOsIs DIAGNOsIs
CRswNp CRssNp CRswNp CRssNp CRswNp CRssNp CRswNp CRssNp
– – – 114 545 198 227 12 16 215 169
+ – – 10 56 23 24 –––– 1 29 18
– + – 9 26 16 13 1 1 9 8
– – + 23 44 44 21 6 1 67 18
+ + – 1 1 1 –––– –––– 1 6 1
+ – + 5 11 16 7 2 –––– 27 6
– + + 12 6 40 13 –––– –––– 52 13
+ + + –––– –––– 8 3 1 –––– 16 4
razem 174 689 346 308 22 20 421 237
„+” indicates the occurrence of a given disease, „–” means the absence of a given disease. 
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the CRSsNP phenotype. Of the 10 patients with asthma, 9 were 
diagnosed with CRSwNP, and in the group of 32 patients without 
asthma – 59.38% had CRSsNP.
ESS 4 – CRS phenotype vs. comorbidities
In the ESS 4 group, the relationship between the phenotype and 
the existence of allergies is important (P = 0.0358). In the group of 
107 patients with an allergy, 72.9% had CRSwNP, whereas in the 
group of 551 patients without allergy, 62.25% had the same phe-
notype (CRSwNP). Thus, the impact of allergies on the phenotype 
with polyps is found to be significant only in the group subjected 
to the most extensive surgery.
The occurrence of the phenotype with polyps depends essentially 
on the existence of hypersensitivity (P = 0.0038). Of the 109 peo-
ple with hypersensitivity, 76.15% had CRSwNP, whereas of the 549 
people without hypersensitivity, it was 61.57%.
The phenotype is significantly dependent on the coexistence of 
asthma (P < 0.0001). Among the 203 patients with asthma, 79.8% 
had CRSwNP. A total of 59.92% out of 455 patients without asthma 
had the same phenotype.
Multivariate analysis (logistic regression)
Previous one-dimensional analysis enabled the authors to assess 
the impact of each of the three comorbidities on the phenotype 
independently of the other two. In order to further estimate the 
influence of comorbidities (three predictors at the same time) on 
the occurrence of a specific inflammatory phenotype, a logistic 
model was built, in which allergies, asthma and hypersensitivity 
were included as predictors. Of the selected predictors, only asth-
ma and hypersensitivity were statistically significant, P < 0.0001 
and P = 0.0007, respectively. The occurrence of allergies is statisti-
cally insignificant in this model (P = 0.1909). The resulting logistic 
regression equation has the following form: 
logit P = 1.15 x asthma + 0,51 x intolerance – 0,59 (1)
On the basis of the intercept parameter, it can be concluded that the 
chance of occurrence of the CRSwNP phenotype in the group of pa-
tients who did not have any of the analysed comorbidities was 0.55. 
According to the obtained model, there are 64.55% of correctly clas-
sified cases, which indicates an average quality of classification. The 
prediction of the lack of inflammation with polyps is high, i.e. 88%. 
However, the coexistence of asthma and hypersensitivity is not suf-
To assess the relationship between the type of diagnosis and co-
morbidities depending on the extent of surgery, the relationship 
between the diagnosis and comorbidities was analysed individu-
ally in each ESS group. Relevant P–values are provided in Tab. IV.
ESS 1 – CRS phenotype vs. comorbidities
In the ESS 1 group, there is no statistically significant relationship 
between the diagnosis and the occurrence of allergies (p = 0.7887). 
Patients with an allergy accounted for 19.05% in the group with 
polyps and 80.95% in the group without polyps. The distribution 
was similar in the non-allergic group – 20.28%  had CRSwNP, and 
the remaining 79.72% had CRSsNP.
In the case of patients with hypersensitivity, the relationship 
between its occurrence and diagnosis is statistically significant 
(P = 0.0001). Among the patients with hypersensitivity, 40% were 
diagnosed with CRSwNP, and in the group without hypersensitiv-
ity, only 18.82% had polyps.
In the group of patients with asthma, the relationship between its 
occurrence and diagnosis is also statistically significant (P < 0.0001). 
A total of 39.60% of patients with asthma were diagnosed with 
CRSwNP, whereas 82.4% of patients without asthma had CRSsNP.
ESS 2 – CRS phenotype vs. comorbidities
In the ESS 2 group, there was also no statistically significant re-
lationship between the existence of allergies and the type of di-
agnosis. In the group of 82 patients with an allergy, 58.54% were 
diagnosed with CRSwNP. Patients without an allergy diagnosed 
with CRSwNP accounted for a similar percentage, i.e. 52.10% out 
of 572 patients.
The relationship between the existence of hypersensitivity and the 
phenotype is statistically significant (P = 0.0006). Of the 94 pa-
tients with hypersensitivity, 69.15% had the CRSwNP phenotype, 
whereas in the group of 560 patients without hypersensitivity, it 
was 50.18% (CRSwNP).
The relationship between the occurrence of asthma and the pheno-
type is also significant (P < 0.0001). Of the 152 patients with asthma, 
71.05% had the phenotype with polyps, whereas in the group of 502 
patients without asthma, 52.59% had the phenotype without polyps.
ESS 3 – CRS phenotype vs. comorbidities
In the ESS 3 group consisting of 42 patients, only 5 patients had 
an allergy, 4 – hypersensitivity and 10 – asthma. Due to the large 
disproportion in terms of the number of patients with respect to 
the other types of ESS, only the relevant fractions were compared 
in the ESS 3 group.
In the group of 37 patients without an allergy, 19 (51.35%) had the 
CRSwNP phenotype. Three patients with an allergy (60%) had the 
same phenotype. In the case of 4 patients with hypersensitivity, half 
of them had the CRSwNP phenotype. In the group of the remain-
ing 38 patients without hypersensitivity, 18 patients (47.37%) had 
Tab. Iv.  Relationship between particular comorbidities and phenotypes for a specific 
ESS type.
ess 1 ess 2 ess 3 ess 4
Phenotype vs. 
allergy
p = 0,7887 p = 0,2747 --------------- p = 0,0358
Phenotype vs. 
hypersensitivity 
p = 0,0001 p = 0,0006 --------------- p = 0,0038
Phenotype vs. 
asthma
p < 0,0001 p < 0,0001 --------------- p < 0,0001
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on their own material, that the development of the CRSwNP phe-
notype, which occurs in the Caucasians with the predominance 
of Th2 mediators and eosinophilia, was influenced by asthma and 
hypersensitivity to NSAIDs. The level of ECP in uncinate tissues of 
patients with CRSwNP, examined by Weibman [19], was higher in 
asthmatics and AERD patients, which was not observed in the case 
of co-existing allergies. This confirms the authors’ observations that 
asthma and NSAIDs hypersensitivity affect the CRS phenotype.
Tan’s study, whose aim was to observe what additional conditions 
occur more frequently in patients with CRS, also found that asthma 
was most strongly associated with the CRSwNP phenotype, where-
as acute rhinosinusitis, otitis media, pneumonia and bronchitis 
were associated with the diagnosis of CRSsNP. In addition, allergic 
rhinitis was present in a similar proportion of cases in both 
sinusitis phenotypes. 
CRSwNP is an inflammatory disease of the nasal cavity and para-
nasal sinuses of unknown cause and often accompanies respiratory 
diseases such as asthma, aspirin hypersensitivity and idiopathic 
bronchiectasis [20–22]. Jarvis [1], based on a multi–centre study 
in 12 European countries, has found a strong correlation between 
CRS and asthma especially when CRS was accompanied by aller-
gic rhinitis. The incidence of asthma is more common in CRSwNP 
patients (7%) than in the general population (4%), predominantly 
in women [23, 24]. 
In the study group, bronchial asthma was present in 466 patients 
(21.02% of 2217). In the group of patients with bronchial asthma, 
319 (68.45%) had polyps, whereas in 147 (31.55%) they were absent. 
Bilodeau [25] has observed that asthma patients with CRSwNP 
have more severe lower airway infections and worse asthma con-
trol compared to patients with CRSsNP.
In the study group, 12.54% of patients had clinically confirmed al-
lergies, by skin prick and/or in vitro tests. The occurrence of IgE-
dependent allergies to environmental allergens in CRS patients is 
estimated to be approximately 60% compared to 30–40% in the 
case of the general population. It is suggested that it may support 
rather than cause eosinophilic mucositis [2, 26]. The results of the 
multivariate analysis performed by the authors did not show the 
impact of allergies on the CRS phenotype. Similar results were 
obtained by Li Qc [27] in the study of 210 patients, which showed 
no relationship between the presence of atopy and polyps. Al-
though allergies do not affect the CRS phenotype, hypersensitivity 
to NSAID seems to be strongly related to the presence of polyps.
AERD is characterized by hypersensitivity to aspirin, asthma and 
CRSwNP, and occurs in about 1% of the population, including 
4.3%–20% of asthmatics and 14–22% of patients with polyps [11, 
28–31]. In the studied material, hypersensitivity to NSAIDs was 
present in 262 cases (11.82% of the 2217 operated patients). The 
authors of the study confirmed the prevalence of asthma and hy-
persensitivity to NSAIDs in CRSwNP patients, especially in women. 
Women accounted for 65.27%, and men for 34.73%. Patients with 
aspirin hypersensitivity often have nasal polyps and asthma. This 
unique endotype is associated with tissue eosinophilia and an in-
crease in the production of leukotrienes [16, 31]. Yamaguchi [32] 
ficient to predict the occurrence of inflammation with polyps (the 
prediction is only 34%). By interpreting the calculated OR, it can 
be stated that the possibility of occurrence of the CRSwNP pheno-
type in the group of people with asthma is more than 3 times higher 
than in the group without diagnosed asthma (OR = 3.16). People 
who have hypersensitivity to NSAIDs have a 70% greater probabil-
ity (OR = 1.67) of developing inflammation with polyps than people 
who do not have hypersensitivity. However, in the case of allergies, 
OR is only 1.19, so the chance of occurrence of the CRSwNP pheno-
type in the group of people with allergies is slightly higher (by about 
20%) than in the group of people without allergies.
DIsCUssION
Rhinosinusitis is defined as inflammation of the nose and paranasal 
sinuses characterized by 2 or more symptoms, one of which should be 
either nasal obstruction or nasal discharge. Other symptoms can be 
facial pain, reduction or loss of smell, or both. Chronic rhinosinusitis 
is defined as symptoms lasting at least 12 weeks without complete 
resolution [11]. The authors of the study limited their observations 
to two CRS phenotypes distinguished on the basis of the presence 
of polyps revealed by nasal endoscopy. In the study group of 2217, 
there were 56.56% (1254) of patients with CRSsNP and 43.44% (963) 
with CRSwNP. The study has shown that CRSsNP is more frequent 
in women (616 out of 1021 women, 60.33%) than men (638 out of 
1196 men, 53.34%). However, a higher percentage of men (558 out 
of 1196, 46.66%) than women (405 out of 1021, 39.67%) had the 
CRSwNP phenotype. A similar observation was made by Tan [15], 
who presented the results of retrospective observations of 446,480 
clinic primary care patients in the years 2001–2010. CRSwNP was 
diagnosed in 595 patients and CRSsNP in 7523, CRSwNP was more 
common among men (54.5%) and CRSsNP among women (58.2%).
It should be borne in mind that there are other phenotypes. CRS 
can be clinically divided according to its severity (mild, moderate 
and severe), duration of inflammation (acute and chronic), colour 
of secretions, whether it is responsive or not to conventional ther-
apy, and also according to the degree of disease control (fully con-
trolled, partially controlled and uncontrolled inflammation) [16]. 
Certain subtypes of CRS, such as cystic fibrosis, primary ciliary 
dyskinesia, antrochoanal polyps, and fungal disease (allergic and 
invasive), systemic diseases, or immune deficiency are not specif-
ically mentioned in the evidence-based guidelines because their 
medical treatment might not differ substantially from other phe-
notypes of rhinosinusitis [6, 16]. Clinical phenotypes do not pro-
vide full insight into all underlying cellular and molecular patho-
physiologic mechanisms of CRS. This heterogeneity supports the 
concept that CRS consists of multiple biological endotypes, which 
might be defined by corresponding biomarkers [16]. The endotype 
of inflammation with the predominance of IL-4, IL-5, IL-10, IL-13 
is associated with Th2-type lymphocytes. These interleukins influ-
ence the growth and proliferation of B lymphocytes [17], whereas 
under the influence of IL-5, eosinophilic inflammation develops 
within the sinus mucous membrane, usually of considerable severity.
A similar mechanism of inflammation was observed in bronchial 
asthma regardless of its phenotype [18]. The authors showed, based 
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findings of authors from the UK and North America, highlight-
ing better postoperative outcomes in patients with CRSwNP who 
underwent extensive surgery, especially when they were affected 
by asthma and AERD. It should be remembered that apart from 
asthma and hypersensitivity accompanying CRSwNP, better post-
operative results are obtained by performing extensive ESS also in 
other, not only neoplastic, sinus diseases [36]. The serum IgE level 
in patients with an allergy is a stimulant factor for more frequent 
recommendations for surgical treatment, but there was no differ-
ence in the outcomes of conservative and surgical treatment in 
patients with and without atopy [37, 38]. A higher level of ECP in 
uncinate tissues and nasal polyps significantly correlates with ra-
diographic severity as determined by CT scores. Mucosal markers 
associated with comorbidities (asthma, atopy, and aspirin sensitiv-
ity) helps better establish the concept of unified airway inflamma-
tion [19]. The latest analysis of the clinical and biological param-
eters currently used for phenotyping and endotyping in CRSwNP 
ruled out allergy as a pathophysiological factor, which confirms 
our results of statistical analysis [39]. The study confirms the in-
fluence of eosinophilic inflammation with asthma and NSAIDs 
hypersensitivity on the development of the phenotype with pol-
yps, more advanced inflammatory changes in the sinuses and the 
need for more extensive surgery. 
CONCLUsIONs
1.  Patients with co-existing asthma and hypersensitivity to NSAIDs 
have a greater chance of developing the CRSwNP phenotype;
2.  In the case of allergies, the probability of the occurrence of 
the CRSwNP phenotype in the group of people with allergies 
is slightly higher (by approx. 20%) than in the group of people 
without allergies;
3.  The impact of allergies, asthma and hypersensitivity on the phe-
notype was observed in the group of patients subjected to the 
most extensive surgery (ESS 4). In the other types of surgery, 
only the relationship between the phenotype with polyps and 
asthma and hypersensitivity was significant.
found that patients with asthma and aspirin hypersensitivity had 
a higher number of eosinophils in the sinus mucous membrane 
and a higher concentration of urinary leukotrienes E4 (U–LTE4) 
in urine than patients with asthma, and good tolerance to NSAIDs. 
Pezato’s studies [33] showed that human DCs were significantly 
increased in CRSwNP compared to control nasal tissue, only the 
expression of pDCs decreased in asthmatic patients and in those 
with no IFN gamma production in the nasal tissue. It was shown 
that pDCs for asthmatic patients were dysfunctional and secret-
ed less innate IFNs in response to rhinovirus exposure. Pezato 
[33] found that pDC decreased in more severe CRSwNP+asthma 
groups and aspirin hypersensitivity groups. These findings provide 
strong support for a unified airway concept in which the mucosal 
surfaces of the upper and lower airways share common pathogens 
and mechanisms of inflammation and innate immunity [15].
Patients with aspirin hypersensitivity were significantly more likely 
to have uncontrolled CRS, which was not observed in the case of 
asthma and atopy [34]. The sinusitis phenotype and presence of 
polyps did not significantly affect the degree of CRS control, as the 
percentages of patients in the three categories of control did not 
differ between CRSwNP and CRSsNP [34]. CRSwNP with accom-
panying asthma is characterized by older age, longer nasal con-
gestion, a higher score in sinus computed tomography and nasal 
endoscopy, and more frequent nasal and sinus reoperations. This 
is especially true of the CRSwNP phenotype with hypersensitiv-
ity to NSAIDs [20, 24]. Bachert [6] reports that during the 12-year 
follow-up, 80% of patients with CRSwNP had polyp recurrence and 
about 37% required reoperation. This concerned mostly patients 
with eosinophil endothelium and AERD [5, 6].
In the studied material, ESS 1 was most commonly performed in 
the CRSsNP phenotype, whereas the CRSwNP phenotype required 
extensive surgery including the opening of all the sinuses, namely 
ESS 4 (it was sporadically limited to the opening of the sphenoid 
sinus only) or ESS 3. The need for reoperation followed by ESS 
3 and 4 has been confirmed by the authors who found a higher 
Lund-MacKay computed tomography score and Lund-Kennedy 
endoscopy score in CRSwNP, especially in patients with atopy 
and hypersensitivity to NSAIDs [7]. Noon [35] has compared the 
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